1 day-26.00%
3 months-38.33%
6 months-95.15%
Current year-98.03%
Current year 0.01
Extreme 0.007
0.65
1 year 0.01
Extreme 0.007
1.48
3 years 0.01
Extreme 0.007
11.42
5 years 0.01
Extreme 0.007
60.66
10 years 0.01
Extreme 0.007
60.66
Manager TitleAgeSince
Chief Executive Officer 67 11/01/2019
Director of Finance/CFO 61 05/03/2020
Chief Operating Officer 60 14/02/2021
Date Insider Type Main position Quantity % Market Cap. Importance
19/07/26 Others

Chief Executive Officer

-1,361,215 3.9017%
19/07/26 Others

Director

-729,626 2.0913%
19/07/26 Others

Chief Financial Officer

-139,616 0.4002%
Change 5-day change 1-year change 3-year change Capi.($)
-26.00%-.--% - - 387K
+0.03%-5.67%+50.74%+76.76% 70.65B
+0.55%-11.72%+5.65%+55.49% 51.22B
-0.45%-0.45%+8.35%+37.19% 48.04B
+0.90%-1.46%+32.32%+32.69% 43.16B
+2.21%-6.61%+302.05%+701.45% 41.57B
-1.15%-3.11%+9.47%+98.83% 39.84B
+0.45%-1.20%+9.11%+43.54% 30.87B
-2.66%-11.49%+42.12%+4.38% 27.53B
-1.16%-1.84%-6.09%-11.99% 24.08B
Average -2.73%-3.42%+50.41%+115.37% 41.88B
Weighted average by Cap. +0.01%-3.47%+52.78%+121.33%
Logo Inotiv, Inc.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Employees
1,996
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Inotiv, Inc.
  1. Stock Market
  2. Stocks
  3. NOTV Stock